These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 22806387)

  • 1. Contribution of blocked potassium current conductance and increased conductance of persistent sodium current to the afterdischarge in myelinated neuron.
    Wu SN; Lo YC; Chen BS; Cheung So E; Chen LT
    Muscle Nerve; 2012 Aug; 46(2):297-9; author reply 300. PubMed ID: 22806387
    [No Abstract]   [Full Text] [Related]  

  • 2. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit.
    Dimitrov AG; Dimitrova NA
    Muscle Nerve; 2012 Mar; 45(3):403-11. PubMed ID: 22334175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
    Park SB; Lin CS; Krishnan AV; Kiernan MC
    Cancer Chemother Pharmacol; 2011 May; 67(5):1189-90; author reply 1191-2. PubMed ID: 21327679
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy.
    Resta F; Micheli L; Laurino A; Spinelli V; Mello T; Sartiani L; Di Cesare Mannelli L; Cerbai E; Ghelardini C; Romanelli MN; Mannaioni G; Masi A
    Neuropharmacology; 2018 Mar; 131():403-413. PubMed ID: 29339292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
    Sittl R; Carr RW; Fleckenstein J; Grafe P
    Neurotoxicology; 2010 Dec; 31(6):694-700. PubMed ID: 20670646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
    Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
    Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
    Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
    Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ion channel dysfunction and peripheral nerve disorders].
    Lefaucheur JP
    Rev Neurol (Paris); 2001 May; 157(5):477-9. PubMed ID: 11438767
    [No Abstract]   [Full Text] [Related]  

  • 9. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
    J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
    [No Abstract]   [Full Text] [Related]  

  • 10. The pain with platinum: oxaliplatin and neuropathy.
    Kiernan MC
    Eur J Cancer; 2007 Dec; 43(18):2631-3. PubMed ID: 17977714
    [No Abstract]   [Full Text] [Related]  

  • 11. Different effects of blocked potassium channels on action potentials, accommodation, adaptation and anode break excitation in human motor and sensory myelinated nerve fibres: computer simulations.
    Stephanova DI; Mileva K
    Biol Cybern; 2000 Aug; 83(2):161-7. PubMed ID: 10966055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations.
    Oldenburg J; Fosså SD
    Acta Oncol; 2009; 48(6):804-6. PubMed ID: 19484592
    [No Abstract]   [Full Text] [Related]  

  • 13. The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy.
    Argyriou AA; Polychronopoulos P; Chroni E
    Oncologist; 2007 Nov; 12(11):1371-2; author reply 1372-3. PubMed ID: 18055858
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement.
    Dunlap B; Paice JA
    J Support Oncol; 2006 Sep; 4(8):398-9. PubMed ID: 17004514
    [No Abstract]   [Full Text] [Related]  

  • 15. The case of the tingling toes.
    Eisenberg S
    ONS Connect; 2011 Sep; 26(9):17. PubMed ID: 21954796
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity.
    Cavaletti G; Ceresa C; Nicolini G; Marmiroli P
    Anticancer Res; 2014 Jan; 34(1):483-6. PubMed ID: 24403505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons.
    Benoit E; Brienza S; Dubois JM
    Gen Physiol Biophys; 2006 Sep; 25(3):263-76. PubMed ID: 17197725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nociceptive response to innocuous mechanical stimulation is mediated via myelinated afferents and NK-1 receptor activation in a rat model of neuropathic pain.
    Pitcher GM; Henry JL
    Exp Neurol; 2004 Apr; 186(2):173-97. PubMed ID: 15026255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peripheral neuropathy induced by anticancer drugs].
    Oishi R; Egashira N
    Fukuoka Igaku Zasshi; 2013 May; 104(5):71-80. PubMed ID: 23885391
    [No Abstract]   [Full Text] [Related]  

  • 20. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation.
    Di Cesare Mannelli L; Pacini A; Matera C; Zanardelli M; Mello T; De Amici M; Dallanoce C; Ghelardini C
    Neuropharmacology; 2014 Apr; 79():37-48. PubMed ID: 24225197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.